Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Value Investing -- Ignore unavailable to you. Want to Upgrade?

To: Spekulatius who wrote (47261)	4/2/2012 12:53:01 PM
From: Paul Senior	Respond to of 78753

Healthcare: COV. Okay, following you and grommit and closing my COV position. Started a tracking position last month in HSP (Hospira); I give up on it now, and am out at breakeven. I like TEVA at current price, and I'm in for a few shares. 1) IF the consensus analyst expectation for earnings is correct, the forward (12/'13) p/e is 7.5 on current stock price. That would make the stock very inexpensive in my view. (Assuming too that '14 earnings won't be down.) finance.yahoo.com 2) Teva has a strategy to grow by acquisitions. I generally don't like this idea, because it places the the acquiring company and its stockholders in a position of presuming the acquirer can manage acquisitions better than the managers who are already in there. However, I do like the idea of borrowing at very low rates to take advantage of current opportunities. Gutsy moves in fearful times. reuters.com